Tech Company Financing Transactions
Third Harmonic Bio Funding Round
On 2/25/2022, Third Harmonic Bio raised $105 million in Series B financing from General Atlantic, Atlas Venture and BVF Partners.
Transaction Overview
Company Name
Announced On
2/25/2022
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series B
Investors
Proceeds Purpose
money the company says will be used to further develop its treatment for chronic hives through a phase 1b trial slated for later this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Technology Square, 8th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of an oral KIT inhibitor designed for the treatment of severe allergy and inflammation. The company's product is a cell surface receptor that acts as the master survival and functional regulator of mast cells, enabling patients to have the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Natalie Holles
Chief Medical Officer
Stephen Yoo
Chief Operating Officer
Howard E. Davis
VP - Product Management
Gregg Keaneyq
Browse more venture capital transactions:
Prev: 2/25/2022: Terray Therapeutics venture capital transaction
Next: 2/25/2022: InterCloud venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document funding rounds that are announced publicly. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs